Chronic Kidney Disease Market Size in the 7MM was ~USD 2824 Million in 2023, and it is expected to grow by 2034, according to DelveInsight

The Chronic Kidney Disease Market was valued at ~USD 2824 Million in 2023 and is projected to grow at a robust CAGR during the study period (2020–2034). DelveInsight’s Comprehensive market research provides critical insights into such market trends, enabling stakeholders to understand growth drivers, emerging opportunities, and potential challenges within the Chronic Kidney Disease Market Landscape. By analyzing historical data, current Chronic Kidney Disease Market Dynamics, and future projections, DelveInsight equips pharmaceutical companies, investors, and healthcare professionals with actionable intelligence to make informed strategic decisions, identify investment opportunities, optimize product positioning, and plan research and development initiatives effectively.

The Chronic Kidney Disease Market Size is increasingly guided by biomarker-driven strategies. Chronic Kidney Disease (CKD) is a long-term medical condition characterized by the gradual loss of kidney function over time. The kidneys play a crucial role in filtering waste products, excess fluids, and toxins from the blood, maintaining electrolyte balance, and regulating blood pressure. In CKD, the kidneys become damaged and lose their ability to perform these functions effectively.

DelveInsight’s report, “Chronic Kidney Disease Market Insights, Epidemiology, and Market Forecast-2034,” provides a comprehensive analysis of the Chronic Kidney Disease Market landscape. The report delivers detailed insights into the disease, including historical and projected epidemiology, helping stakeholders understand the prevalence, incidence, and patient demographics across key regions. Additionally, it examines Chronic Kidney Disease Market Dynamics, offering a thorough assessment of current and emerging market trends, treatment patterns, and therapeutic developments. The analysis spans major markets, including the United States, EU4 (Germany, Spain, Italy, France, and the United Kingdom), and Japan, equipping decision-makers with actionable intelligence for strategic planning, investment, and research initiatives.

To know in detail about the Chronic Kidney Disease Market Outlook, drug uptake, treatment scenario, and epidemiology trends, click here @ Chronic Kidney Disease Market Forecast

Key Takeaways from Chronic Kidney Disease Market Report

• In the assessment done by DelveInsight, the estimated total diagnosed prevalent cases of Chronic Kidney Disease in the 7MM were nearly 16 million in 2023.
• The highest total diagnosed prevalent cases of Chronic Kidney Disease were accounted by the US in 2023 (5 million), which are expected to show a rise in the future.
• Among the European countries, the United Kingdom had the highest diagnosed prevalent cases of Chronic Kidney Disease with ~2 million cases, followed by Germany, which had diagnosed prevalent population of ~1 million in 2023. On the other hand, Italy had the lowest prevalent population (731 thousand cases).
• Japan had nearly 3 million total diagnosed prevalent cases of Chronic Kidney Disease in 2023, accounting for approximately 22% in 7MM.
• Based on Severity-specific segmentation, the people in Stage 3 were affected the most by Chronic Kidney Disease in the US, accounting for approximately 2,940 thousand cases in 2023.
• The DelveInsight analysis indicates that among the EU4 and the UK, more females are affected than males, with approximately 3,550 thousand female cases and 3,400 thousand male cases in 2023.
• The leading Chronic Kidney Disease Companies, such as AstraZeneca, Boehringer Ingelheim, Mineralys Therapeutics, ProKidney, Disc Medicine, Regeneron Pharmaceuticals, AION Healthspan, Amgen, Maze Therapeutics, and others.
• Promising Chronic Kidney Disease Therapies such as Zibotentan/Dapagliflozin, Baxdrostat/dapagliflozin, Vicadrostat + Empagliflozin, Lorundrostat, Rilparencel, DISC-0974, Vonsetamig, Etelcalcetide, MZE829, MZE782, and others.

Chronic Kidney Disease Overview

Chronic Kidney Disease (CKD) is a long-term medical condition characterized by the gradual loss of kidney function over time. The kidneys play a crucial role in filtering waste products, excess fluids, and toxins from the blood, maintaining electrolyte balance, and regulating blood pressure. In CKD, the kidneys become damaged and lose their ability to perform these functions effectively. Common causes include diabetes, hypertension (high blood pressure), glomerulonephritis, and inherited kidney disorders such as polycystic kidney disease. In the early stages, CKD may not cause noticeable symptoms, but as the disease progresses, patients may experience fatigue, swelling in the legs and ankles, nausea, loss of appetite, difficulty concentrating, and changes in urination patterns. CKD is typically classified into five stages based on the glomerular filtration rate (GFR), which measures how well the kidneys filter blood. Early detection, lifestyle modifications, blood pressure and blood sugar control, and appropriate medical management can help slow disease progression and reduce the risk of complications such as kidney failure, cardiovascular disease, and the need for dialysis or kidney transplantation.

Get a Free sample for the Chronic Kidney Disease Market Report @ https://www.delveinsight.com/sample-request/chronic-kidney-disease-chronic-renal-failure-market

Key Factors in Chronic Kidney Disease Therapeutics Market

• Rising Global Prevalence of Chronic Kidney Disease

The increasing number of people affected by chronic kidney disease (CKD), largely driven by the growing incidence of diabetes, hypertension, and aging populations, is a major factor fueling the demand for effective CKD therapeutics.

• Growing Burden of Diabetes and Hypertension

Diabetes and high blood pressure are among the leading causes of CKD worldwide. The rising prevalence of these conditions significantly contributes to the expansion of the CKD therapeutics market.

• Advancements in Drug Development

Continuous research and development efforts are leading to the introduction of innovative therapies, including SGLT2 inhibitors, nonsteroidal mineralocorticoid receptor antagonists, and other targeted treatments that help slow CKD progression.

• Increasing Awareness and Early Diagnosis

Improved screening programs and greater awareness among healthcare professionals and patients are enabling earlier detection of CKD, which supports timely treatment and drives demand for therapeutics.

• Strong Pipeline of Emerging Therapies

Pharmaceutical companies are actively investing in CKD research, resulting in a robust pipeline of novel therapies aimed at improving kidney function and reducing disease progression.

• Supportive Government and Healthcare Initiatives

Various public health initiatives and awareness campaigns focused on kidney health are encouraging early diagnosis and treatment, positively influencing the CKD therapeutics market.

• Growing Healthcare Expenditure

Increased healthcare spending across developed and emerging economies is facilitating access to advanced treatments and supporting market growth.

• Technological Advancements in Disease Management

Improvements in diagnostic technologies, biomarker identification, and personalized medicine approaches are enhancing CKD management and expanding therapeutic opportunities.

• Increasing Focus on Combination Therapies

Healthcare providers are increasingly adopting combination treatment strategies to improve patient outcomes and manage complications associated with chronic kidney disease.

Chronic Kidney Disease Epidemiology Segmentation in the 7MM

The Chronic Kidney Disease Market Report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into-

• Total Prevalent Cases of CKD
• Total Diagnosed Prevalent Cases of CKD
• Gender-specific Diagnosed Prevalent Cases of CKD
• Age-specific Diagnosed Prevalent Cases of CKD
• Stage-specific Diagnosed Prevalent Cases of CKD
• Complication-specific Diagnosed Prevalent Cases of CKD
• Etiology-specific Diagnosed Prevalent Cases of CKD

Download the report to understand which factors are driving Chronic Kidney Disease Epidemiology trends @ Chronic Kidney Disease Epidemiology Forecast

Recent Development in the Chronic Kidney Disease Treatment Landscape

• In Sept 2025, eGenesis received FDA clearance for its Investigational New Drug (IND) application to start clinical trials of EGEN-2784, a genetically engineered porcine kidney, for treating end-stage kidney disease (ESKD). The Phase 1/2/3 study will evaluate safety and efficacy in dialysis-dependent patients aged 50 and older on the transplant waitlist.
• In July 2025, the FDA endorsed eGFR slope for rilparencel's accelerated approval in advanced CKD, with PROACT 1 supporting both pathways.
• In May 2025, ProKidney reported strategic updates to its Phase III program, prioritizing the US-based PROACT 1 trial and discontinuing the ex-US PROACT 2 study to accelerate enrollment.
• In March 2025, the FDA expanded the approval of Furoscix to include the treatment of edema in patients with chronic kidney disease, including nephrotic syndrome.
• In March 2025, the FDA approved an expanded indication for furosemide injection (Furoscix; scPharmaceuticals, Inc.) to treat edema in adult patients with chronic kidney disease (CKD), including nephrotic syndrome. The expanded treatment is expected to be available by April 2025. This approval follows the FDA's acceptance of the supplemental new drug application in July 2024.
• In January 2025, the FDA approved a new indication for semaglutide to reduce the risk of worsening kidney disease, kidney failure, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease, according to Novo Nordisk.

Chronic Kidney Disease Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential Chronic Kidney Disease drugs recently launched in the Chronic Kidney Disease market or expected to get launched during the study period. The analysis covers Chronic Kidney Disease Market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share. The report also covers the Chronic Kidney Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Chronic Kidney Disease Therapies and Companies

• Epoetin Alfa: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
• PF-00489791: Pfizer
• Baricitinib: Duke University
• Pegol-Sihematide: Jiangsu Hansoh Pharmaceutical Co., Ltd.
• OPC-41061: Otsuka Pharmaceutical Co. Ltd
• Sitagliptin: Merck Sharp & Dohme LLC

To know more about Chronic Kidney Disease Companies working in the treatment market, visit @ Chronic Kidney Disease Clinical Trials and Therapeutic Assessment

Chronic Kidney Disease Market Drivers

• Rising Prevalence of Chronic Kidney Disease: The growing number of patients suffering from CKD worldwide is a major factor driving market growth. Lifestyle-related conditions such as diabetes and hypertension significantly increase the risk of developing kidney disease.
• Increasing Burden of Diabetes and Hypertension: Diabetes and high blood pressure are the leading causes of CKD. The rising global incidence of these conditions is contributing to a larger CKD patient population, thereby boosting demand for effective treatments.
• Growing Aging Population: Elderly individuals are more susceptible to kidney function decline. As the global geriatric population continues to increase, the prevalence of CKD is expected to rise, supporting market expansion.
• Advancements in Treatment Options: Continuous research and development activities have led to the introduction of innovative therapies, including targeted drugs and novel treatment approaches, which are improving patient outcomes and driving market growth.
• Improved Diagnostic Technologies: Advancements in diagnostic methods and early detection techniques are enabling healthcare providers to diagnose CKD earlier, allowing timely treatment and increasing the demand for therapeutic interventions.
• Increasing Awareness and Screening Programs: Government initiatives, healthcare campaigns, and awareness programs about kidney health and early disease detection are encouraging more people to undergo screening and treatment.
• Expansion of Healthcare Infrastructure: Improvements in healthcare systems, particularly in emerging economies, are enhancing access to CKD diagnosis and treatment, contributing to market growth.
• Growing Investment in Nephrology Research: Pharmaceutical and biotechnology companies are increasingly investing in nephrology research, leading to the development of new drugs and therapeutic strategies for CKD management.

Chronic Kidney Disease Market Barriers

• Late Diagnosis and Underdiagnosis: Chronic Kidney Disease (CKD) often progresses silently in its early stages, with many patients remaining undiagnosed until the disease has significantly advanced. This delays treatment initiation and limits the effectiveness of available therapies.
• High Treatment Costs: The management of CKD, particularly in advanced stages requiring dialysis or kidney transplantation, involves substantial healthcare expenses. The high cost of long-term treatment and newer therapeutic options can restrict patient access in many regions.
• Limited Availability of Curative Treatments: Most currently available CKD therapies focus on slowing disease progression rather than providing a complete cure. This limitation creates challenges in significantly improving patient outcomes and reducing disease burden.
• Side Effects of Existing Therapies: Some commonly used CKD treatments may cause adverse effects or complications, which can reduce patient adherence and limit their long-term use.
• Comorbid Conditions: CKD is often associated with other chronic conditions such as diabetes, hypertension, and cardiovascular diseases. These comorbidities complicate treatment strategies and may hinder the effectiveness of CKD-specific therapies.
• Challenges in Clinical Trials: Recruiting patients for CKD clinical trials and maintaining long-term follow-up can be difficult due to the slow progression of the disease and strict eligibility criteria.
• Limited Awareness and Screening Programs: In several regions, especially in developing countries, inadequate awareness and lack of routine screening programs contribute to delayed diagnosis and insufficient disease management.
• Healthcare Infrastructure Limitations: In many parts of the world, limited access to nephrologists, dialysis centers, and advanced treatment facilities restricts effective CKD management and slows market expansion.

Scope of the Chronic Kidney Disease Market Report

• Coverage- 7MM
• Study Period- 2020-2034
• Chronic Kidney Disease Companies- AstraZeneca, Boehringer Ingelheim, Mineralys Therapeutics, ProKidney, Disc Medicine, Regeneron Pharmaceuticals, AION Healthspan, Amgen, Maze Therapeutics, and others.
• Promising ANCA-associated Vasculitis Therapies- Zibotentan/Dapagliflozin, Baxdrostat/dapagliflozin, Vicadrostat + Empagliflozin, Lorundrostat, Rilparencel, DISC-0974, Vonsetamig, Etelcalcetide, MZE829, MZE782, and others.
• Chronic Kidney Disease Therapeutic Assessment: Chronic Kidney Disease current marketed and emerging therapies
• Chronic Kidney Disease Market Dynamics: Chronic Kidney Disease market drivers and Chronic Kidney Disease market barriers
• Chronic Kidney Disease Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Chronic Kidney Disease Unmet Needs, KOL’s views, Analyst’s views, Chronic Kidney Disease Market Access and Reimbursement

Discover more about therapies set to grab the major Chronic Kidney Disease Market Share @ Chronic Kidney Disease Treatment Market

Table of Contents

1. Key Insights

2. Chronic Kidney Disease Market Report Introduction

3. Chronic Kidney Disease Executive Summary

4. Chronic Kidney Disease Key Events

5. Chronic Kidney Disease Epidemiology and Market Forecast Methodology

6. Chronic Kidney Disease Market Overview at a Glance

7. Chronic Kidney Disease: Background and Overview

8. Chronic Kidney Disease Epidemiology and Patient Population

9. Chronic Kidney Disease Patient Journey

10. Chronic Kidney Disease Marketed Drugs

11. Chronic Kidney Disease Emerging Drugs

12. Chronic Kidney Disease: 7MM Analysis

13. Chronic Kidney Disease Unmet Needs

14. Chronic Kidney Disease SWOT Analysis

15. Chronic Kidney Disease KOL Views

16. Chronic Kidney Disease Market Access and Reimbursement

17. Appendix

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.